Please login to the form below

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

BMS links up with Molecular Templates for oncology research collaboration

MTEM’s pipeline includes a number of oncology-directed assets, such as a first-generation ETB (MT-3724) in phase 2 development for pre-treated diffuse large B-cell lymphoma (DLBCL)

Latest news

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

resulted in objective clinical responses in 47% of patients with mantle cell lymphoma (MCL) and 80% of patients with diffuse large B-cell lymphoma (DLBCL). ... In the DLBCL group, four of the five patients who were treated with VLS-101 had objective
NICE recommends Roche’s Polivy for B-cell lymphoma

drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL). ... The new treatment option is great news for patients and clinicians, considering that the prognosis for relapsed
IMV preps pivotal trials for ovarian cancer T cell therapy

B-cell lymphoma (DLBCL) and another spanning multiple solid tumour types.
EU grants conditional approval to Roche's lymphoma drug Polivy

The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and CLL. ... MorphoSys has already filed tafasitamab with the FDA, as a treatment for patients with r/r DLBCL, and expects a decision by mid-2020.

More from news
Approximately 9 fully matching, plus 58 partially matching documents found.

Latest Intelligence

European biotech: a new generation of leaders emerges

The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with
Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
Deal Watch January 2018

pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics
Pharma deals in April 2015

its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account Director - Med Comms Agency: Salary TBC

MEDICAL WRITER - HOME WORKING: Salary TBC

ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER: Salary TBC

SENIOR MEDICAL WRITER: Salary TBC

SENIOR ACCOUNT MANAGER - MEDICAL COMMUNICATIONS: Salary TBC

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial: What key things do you need to remember to reach patients living with Alzheimer’s disease?...
Integrating competitive intelligence into business development, licensing and M&A strategy: The advantages of partnering with a competitive intelligence or knowledge management team...
Reaching patients and HCPs during the pandemic: COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...